EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer

Iseult M Browne iD, Alicia F C Okines iD

Cancers · 18.06.2024 · 16 (12) · 2259

DOI: 10.3390/cancers16122259 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 18.06.2024. Verfasst von Iseult M Browne und 1 weiteren Autor:innen. Beteiligte Einrichtung: Breast Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The PI3K/AKT/mTOR signalling pathway is one of the most frequently activated pathways in breast cancer and also plays a central role in the regulation of several physiologic functions. There are major efforts ongoing to exploit precision medicine by developing inhibitors that target the three kinases (PI3K, AKT, and mTOR). Although multiple compounds have been developed, at present, there are just three inhibitors approved to target this pathway in patients with advanced ER-positive, HER2-negative breast cancer: everolimus (mTOR inhibitor), alpelisib (PIK3CA inhibitor), and capivasertib (AKT inhibitor). Like most targeted cancer drugs, resistance poses a major problem in the clinical setting and is a factor that has frequently limited the overall efficacy of these agents. Drug resistance can be categorised into intrinsic or acquired resistance depending on the timeframe it has developed within. Whereas intrinsic resistance exists prior to a specific treatment, acquired resistance is induced by a therapy. The majority of patients with ER-positive, HER2-negative advanced breast cancer will likely be offered an inhibitor of the PI3K/AKT/mTOR pathway at some point in their cancer journey, with the options available depending on the approval criteria in place and the cancer’s mutation status. Within this large cohort of patients, it is likely that most will develop resistance at some point, which makes this an area of interest and an unmet need at present. Herein, we review the common mechanisms of resistance to agents that target the PI3K/AKT/mTOR signalling pathway, elaborate on current management approaches, and discuss ongoing clinical trials attempting to mitigate this significant issue. We highlight the need for additional studies into AKT1 inhibitor resistance in particular.

Schlagwörter

Stichwörter der Autor:innen

AKT inhibitorsER-positive breast cancerPI3K inhibitorsadvanced breast cancermTOR inhibitorstreatment resistance

Autor:innen und Institutionen

  • Breast Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.

ORCID-Profile: Iseult M Browne, Alicia F C Okines

Zitieren

APA

Browne, I. M., & Okines, A. F. C. (2024). Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer. Cancers, 16(12), 2259. https://doi.org/10.3390/cancers16122259

Vancouver

Browne IM, Okines AFC. Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer. Cancers. 2024;16(12):2259. doi:10.3390/cancers16122259

BibTeX
@article{Browne2024,
  author = {Browne, Iseult M and Okines, Alicia F C},
  title = {Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {12},
  pages = {2259},
  doi = {10.3390/cancers16122259}
}
Kostenlos starten →